港股泡泡玛特午后涨超5%，成交额超20亿港元。 无需港股通，A股账户就能T+0买港股>> ...

智通财经6月4日电，泡泡玛特午后快速拉升，现涨超5%，成交额超22亿港元。 ...

国内金饰价格普遍持稳 金十数据6月4日讯，金十图示：国内多家黄金珠宝品牌公布的境内足金首饰价格普遍较昨日维持不变，报1020元/克。周生生和 老庙黄金足金饰品价格小幅下跌。 | HOWTAISENG | 周大生足金999 | 1020 元/克 | | --- | --- | --- | | 1 | 菜百首饰足金999饰品 | 995.00 元/克 | | H 附近其 | 潮宏基足金(首饰摆件) | 1020 元/克 | | TSL 謝瑞朗 | 谢瑞麟足金饰品 | 1020 元/克 | | 3 王中 | 金至尊足金999 | 1020 元/克 | | 周六福 | 周六福足金999 | 1000 元/克 | @ JIN10. COM 0.CO 金十数据 | 一个交易工具 ...

Group 1 - Miniso has reportedly hired JPMorgan and UBS to assist its subsidiary TOP TOY in an IPO in Hong Kong [1]

Core Viewpoint - The Hong Kong stock market experienced a slight decline, but the innovative drug sector showed significant movement, with Innovent Biologics surging 17% in a single day, leading to a strong rebound in related ETFs [1] Group 1: Market Performance - The largest thematic ETF in the Hong Kong market, the Hong Kong Innovative Drug ETF (513120), was the most actively traded, with a turnover rate exceeding 38% and a transaction volume close to 40 billion yuan by 11:30 AM [1] - The surge in innovative drugs is attributed to multiple industry catalysts, enhancing market confidence [1] Group 2: Industry Catalysts - The China National Medical Products Administration issued 11 innovative drug approvals at the end of May, boosting expectations for commercialization among pharmaceutical companies [1] - High-quality research results from domestic innovative drugs were showcased at the American Society of Clinical Oncology (ASCO) and American College of Rheumatology (ACR) meetings, validating the value of leading pharmaceutical pipelines and business development capabilities [1] Group 3: Investment Strategy - Investors are encouraged to construct a strategy that includes the Hong Kong Innovative Drug ETF (513120), Medical ETF Leader (560260), and Pharmaceutical and Health ETF (159938) to capture opportunities across the entire innovative drug supply chain [1] - The three ETFs form a closed loop: the Hong Kong Innovative Drug ETF addresses R&D breakthroughs, the Medical ETF Leader focuses on industrialization, and the Pharmaceutical and Health ETF captures commercialization [2] Group 4: ETF Details - The Hong Kong Innovative Drug ETF (513120) tracks the China Securities Hong Kong Innovative Drug Index, with a current P/E ratio of 27 times and a valuation at the 18th percentile historically [4] - The Medical ETF Leader (560260) focuses on medical devices and services, with a P/E ratio of 31 times and a valuation at the 20th percentile historically [4] - The Pharmaceutical and Health ETF (159938) covers the pharmaceutical and health industry, with a P/E ratio of 35 times and a valuation at the 43rd percentile historically [4]

据财政部，2025年6月3日，上海合作组织成员国财长和央行行长会议以线上线下相结合的方式在北京举 行。会议主要讨论了宏观经济形势与政策、上合组织财金合作等议题。财政部部长蓝佛安和中国人民银 行行长潘功胜共同主持会议。 ...

Group 1 - The core point of the article is that Hansoh Pharmaceutical has received approval from the UK Medicines and Healthcare products Regulatory Agency for the marketing of Amivantamab tablets [1]

Group 1 - The Hang Seng Index increased by 0.72% during the midday trading session [1] - The Hang Seng Tech Index rose by 1.01% [1] - Innovent Biologics saw a significant increase of over 15% in its stock price [1] Group 2 - Meituan's stock price increased by over 4% [1] - Pop Mart's stock price rose by over 3% [1]

Core Viewpoint - Pop Mart has gained significant popularity overseas, evidenced by a recent incident in the UK where a large-scale brawl occurred over the limited edition Labubu toy, leading to the company's decision to halt sales in the UK [1]. Group 1: Company Performance and Market Reaction - Pop Mart's stock price surged, reaching a historical high of 235.6 HKD on June 3, with a market capitalization exceeding 310 billion HKD, reflecting a year-to-date increase of over 160% [3][4]. - Despite the stock's impressive performance, many retail investors express skepticism, believing it to be another bubble, while institutional investors have largely missed out on this capital feast [4][5]. Group 2: Investment Strategies and Challenges - Institutional investors have struggled to adapt to the changing consumer landscape, often entering and exiting positions at inopportune times, leading to significant losses [6][7]. - The traditional investment mindset, focused on established metrics like brand strength and cash flow, has hindered many fund managers from recognizing the potential of Pop Mart's innovative business model [8][12]. Group 3: New Consumer Trends and Future Outlook - Pop Mart's success is attributed to its unique IP creation model, which has allowed it to generate significant revenue from overseas markets, with international sales projected to reach 30% by mid-2024 [9][10]. - The company has effectively tapped into the emotional and identity-driven consumption trends of the Z generation, which is expected to control 27% of global disposable income by 2025 [15][16]. - The shift in consumer preferences towards emotional fulfillment and collectible items indicates a broader transformation in the consumption landscape, challenging traditional investment paradigms [17]. Group 4: Market Dynamics and Risks - The concentrated ownership structure of Pop Mart, with the top 25 shareholders holding over 85% of shares, raises concerns about stock price volatility and market sensitivity to liquidity [16]. - Despite potential risks, the transition in consumption investment logic is seen as inevitable, with other brands also demonstrating the power of new consumer trends [17].

beauty 等。 盈利预测与投资建议：我们预测公司25~27 年归母净利润分别为10.6/13.8/17.4亿元，对应25~27 年EPS 为2.65/3.47/4.37 元，25/26/27 年PE 为23/18/14倍，结合绝对和相对估值结果，给予公司目标价86 港 元，首次覆盖给予"买入"评级。 公司抓住了抖音平台的发展机遇，2023~2024 年业绩高速增长，2022~2024 年收入、归母净利润年复合 增速分别为59.3%/130.5%；2024 年公司实现营业收入67.93 亿元，同比增长62.1%，归母净利润7.81 亿 元，同比增长69.4%。 行业分析：化妆品行业增长和竞争并存，下沉市场、细分赛道蕴藏机遇中国化妆品行业规模增速2020 年开始呈现波动，2024 年行业规模为5372 亿元、同比下降2.0%。其中，分定位来看，2024 年出现大众 定位化妆品的行业规模增长表现好于高端定位的局面，可能显示消费者对性价比的偏好正在提升。细分 品类方面，彩妆、婴幼儿护理行业规模表现相对突出、好于化妆品行业总体。 竞争格局方面，国产品牌凭借线上渠道突围，线上渠道呈现平台格局分化，抖音凭借内容异军突起 ...